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Abstract 
Late stage Parkinson’s disease (PD) patients were commonly observed with 
other non-motor comorbidities such as dementia and psychosis. While abnormal iron 
level in the substantia nigra was clinically accepted as a biomarker of PD, it was also 
suggested that the increased iron deposition could impair other brain regions and induce 
non-motor symptoms. A new Magnetic Resonance Imaging (MRI) called Quantitative 
Susceptibility Mapping (QSM) has been found to measure iron concentration in the 
grey matter reliably. In this study, we investigated iron level of different subcortical 
and limbic structures of Parkinson’s disease (PD) patients with and without dementia 
by QSM.  
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QSM and volumetric analysis by MRI were performed in 10 PD dementia (PDD) 
patients (73 ± 6 years), 31 PD patients (63 ± 8 years) and 27 healthy controls (62 ± 7 
years). No significant differences were observed in the L-Dopa equivalent dosage for 
the two PD groups (p = 0.125).  
 
Putative iron content was evaluated in different subcortical and limbic 
structures of the three groups, as well as its relationship with cognitive performance. 
One-way ANCOVA with FDR adjustment at level of 0.05, adjusted for age and gender, 
showed significant group differences for left and right hippocampus (p = 0.015 & 
0.032, respectively, BH-corrected for multiple ROIs) and right thalamus (p = 0.032, 
BH-corrected). Post-hoc test with Bonferroni’s correction suggested higher magnetic 
susceptibility in PDD patients than healthy controls in the left and right hippocampus 
(p = 0.001 & 0.047, respectively, Bonferroni’s corrected), while PD patients had 
higher magnetic susceptibility than the healthy controls in right hippocampus and 
right thalamus (p = 0.006 & 0.005, respectively, Bonferroni’s corrected). PDD patients 
also had higher susceptibility than the non-demented PD patients in left 
hippocampus (p = 0.046, Bonferroni’s corrected). The magnetic susceptibilities of the 
left and right hippocampus were negatively correlated with the Mini-Mental State 
Examination score (r = -0.329 & -0.386, respectively; p < 0.05).  
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This study provides support for iron accumulation in limbic structures of PDD 
and PD patients and its correlation with cognitive performance, however, its putative 
involvement in development of non-motor cognitive dysfunction in PD pathogenesis 
remains to be elucidated. 
 
Highlights 
 This study explore association between brain iron and cognitive impairment in 
PD. 
 QSM shows iron accumulation in the hippocampus of PDD patients. 
 Iron in the hippocampus is correlated with cognitive function of PD patients. 
 
Keywords: dementia, Parkinson’s disease, Magnetic Resonance Imaging, Quantitative 
Susceptibility Mapping, iron deposition, hippocampus, amygdala 
 
 
 
 
1. Introduction 
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  Patients with Parkinson’s disease (PD) in advanced stage may develop 
concomitant non-motor symptoms related to neuropsychiatric or cognitive 
disturbances (Tolosa et al., 2014), significantly exacerbating their disability. One of 
the most common non-motor manifestations in Parkinson’s disease is dementia 
(PDD), for which the prevalence and annual incidence are estimated at respectively 
30 – 40% (Burn and Yarnall, 2014; Emre et al., 2007; Goetz et al., 2008) and 10% 
(Goetz et al., 2008) of PD patients. This indicates that such potentially disabling 
complication of PD should be carefully addressed in clinical management. Patients 
with PDD generally experience significant cognitive decline, distinct from that due to 
Alzheimer’s disease (AD), including impairment of executive function, attention, 
visuospatial function, constructional praxis, and memory (Burn and Yarnall, 2014; 
Goetz et al., 2008). Notably, greater deficits in executive and visuospatial functions 
and lesser in language functions are observed in PDD than AD (Burn and Yarnall, 
2014; Goetz et al., 2008). While some studies propose an association between 
Apolipoprotein E (APOE) and the dementia symptoms of PDD (Irwin et al., 2012; 
Monsell et al., 2014), others do not support such claims (Burn and Yarnall, 2014; 
Mengel et al., 2016), thus rendering the mechanism underlying development of 
dementia in PD and its relationship with the AD-type dementia to be inconclusive. 
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 Various studies have been performed to identify abnormalities in the brain of 
PDD patients. Imaging studies such as Magnetic Resonance Imaging (MRI) reported 
structural change in the hippocampus and amygdala of PDD patients, suggesting that 
the dementia symptom in PD might be associated with limbic atrophy (Aarsland et al., 
2008); one study by Kalaitzakis et al. also suggested the involvement of limbic system 
in PDD, with the association between dementia and α-synuclein pathology in the 
limbic structures being observed (Kalaitzakis et al., 2009). These findings suggest 
plausible association between limbic abnormality and the dementia symptom, and 
that further investigation of the involvement of limbic structures in PDD is warranted. 
 
Abnormal subcortical iron deposition in PD has been postulated to be the cause 
of the degeneration of dopaminergic neurons in the substantia nigra pars compacta 
(Hare et al., 2013; Jenner, 1991; Rouault and Cooperman, 2006). In a hypothesis of 
PD neurodegeneration, iron is suggested to induce α-synuclein pathology (Hare et al., 
2013). α-synuclein is a presynaptic neuronal protein that is abundant in human brain 
and can be found in different brain regions including neocortex, hippocampus, 
substantia nigra, thalamus, and cerebellum. Abnormal aggregation of α-synuclein in 
PD patients, a clinical pathological hallmark of the disease, contributes to the 
formation of Lewy bodies which the major component is α-synuclein (Marques and 
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Outeiro, 2012; Stefanis, 2012). Such pathological feature rendered PD to be 
considered as a type of synucleinopathies. Since α-synuclein aggregation has also 
been observed in limbic structures and is itself associated with the onset of dementia 
in PDD, we hypothesize that iron accumulation in PD could also be involved in the 
later overt development of neuropsychiatric symptoms in PD patients.  
 
Quantitative Susceptibility Mapping (QSM) is a novel technique which allows 
the determination of tissue’s bulk magnetic susceptibility distribution from gradient 
echo magnetic resonance phase images. A previous study by Langkammer et al. 
reported a strong linear correlation between chemically determined iron 
concentration and bulk magnetic susceptibility in grey matter structures 
(Langkammer et al., 2012). The objective of this study is to identify the role of 
abnormal iron metabolism in PD-type dementia by comparing the in vivo putative 
iron content measured with QSM, of different subcortical and limbic brain structures 
amongst healthy subjects and PD patients with or without dementia. In addition, any 
association between iron and the expression of dementia and psychotic 
symptomatology in PD is addressed. MR volumetric analysis of the subcortical and 
limbic brain structures is also performed.  
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2. Materials and Methods 
2.1 Participants 
This study was approved by the local Institutional Review Board. The recruited 
participants were divided into three groups based on clinical diagnosis and result of 
neuropsychiatric assessments. A total of 68 participants were recruited with referral 
from experienced physicians. All participants or their caregivers were carefully 
explained for the study by the responsible medical officers before full written 
informed consent was obtained. The study cohort comprised of 10 PDD patients (8 
males, mean age ± S.D. = 73 ± 6 years, mean illness duration ± S.D. = 13 ± 8 years), 31 
non-demented PD patients (17 males, mean age ± S.D. = 63 ± 8 years, mean illness 
duration ± S.D. = 8 ± 5 years) and 27 healthy controls (14 males, mean age ± S.D. = 62 
± 7 years). PD was diagnosed using the UK Parkinson’s Disease Society Brain Bank 
clinical diagnostic criteria (Hughes et al., 1992). PD patients were classified as PDD 
when they fulfilled the level one diagnostic criteria proposed by the Movement 
Disorder Society (MDS) (Dubois et al., 2007; Holden et al., 2016; Vasconcellos and 
Pereira, 2015). Patients with other known neurodegenerative disorders were 
excluded. Severity of motor deficit was assessed with both Section III of Unified 
Parkinson’s Disease Rating Scale (UPDRS-III) and Hoehn & Yahr staging (Hoehn and 
Yahr, 1967). The cumulative L-Dopa Equivalence (mg) of the PD patients were also 
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obtained for the evaluation of the differences between the study cohorts. 
 
2.2 Neuropsychiatric assessments 
Neuropsychiatric status of all subjects were assessed with the following tests: 
Mini-mental State Examination (MMSE) to assess cognitive impairment (Folstein et 
al., 1975); Parkinson Psychosis Rating Scale (PPRS) and Positive and Negative 
Syndrome Scale (PANSS) to examine the severity of psychosis (Friedberg et al., 1998); 
Self-assessment of Montgomery-Åsberg Depression Rating Scale (MADRS-S) to 
measure the severity of depression symptom (Kay et al., 1987; Montgomery and 
Asberg, 1979), and Yale-Brown Obsessive Compulsive Scale (Y-BOCS) to measure 
obsessive-compulsive symptoms (Goodman et al., 1989). The complete 
demographics and the clinical neuropsychiatric profile of all subjects are listed in 
Table 1. 
 
2.3 Image acquisition 
MRI was performed with a Philips Achieva 3.0T MRI Scanner with an 8-channel 
SENSE head coil for reception. Whole brain sagittal T1-weighted images were 
acquired with the 3D T1-TFE sequence with the following parameters: TE/TR = 
3.2/7.0 ms, flip angle = 8°, FOV = 250 x 250 x 155 mm3, matrix size = 256 x 256 x 155, 
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nominal and reconstructed resolution = 0.97 x 0.97 x 1 mm3, number of excitations 
(NEX) = 1. Axial susceptibility weighted images (SWI) images were acquired with a 
velocity-compensated 3D fast-field echo sequence with the following parameters: 
TE/TR = 23/28 ms, flip angle = 15°, FOV = 230 x 230 x 180 mm3, acquisition matrix 
size = 256 x 256 x 180, nominal resolution = 0.9 x 0.9 x 1 mm3, reconstructed 
resolution = 0.45 x 0.45 x 1 mm3, NEX = 1. 
 
2.4 Image post-processing 
QSM computations were performed using MATLAB R2014a. The phase image 
was unwrapped with the Laplacian-based algorithm (Li et al., 2011; Schofield and Zhi, 
2003) and was further processed for background phase removal with RE-SHARP (Sun 
and Wilman, 2014). QSM dipole inversion was performed with the L1-norm 
total-variation-based regularization algorithm with magnitude image as structural 
prior (Bilgic et al., 2014; Bilgic et al., 2012).  
 
Delineation of subcortical and limbic structures was performed with FIRST in FSL. 
FIRST was applied to the affine-registered T1-TFE image for the segmentation of 
bilateral caudate nuclei, putamen, globus pallidus, amygdala, hippocampi, and 
thalamus (Figure 1), which were subsequently converted into binary masks for the 
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region-of-interest (ROI) analysis of regional magnetic susceptibility and regional 
volume. Bilateral substantia nigra, red nuclei and dentate nuclei were manually 
defined (by DTHL supervised by a neuroradiologist, HKFM) on the average magnitude 
image of the control group in the MNI152 standard space. CSF of the lateral ventricle 
was segmented for the normalization purpose. This was performed by the 
segmentation of all CSF using FSL. An ROI which identified the slices of the lateral 
ventricle was delineated for each subject and was subsequently applied to the CSF 
mask to segment the CSF of the lateral ventricle. This ROI was eroded by 1.5 mm to 
avoid partial volume effect.  The delineated structures were converted into binary 
masks, which were then inversely warped back to the subject’s native space for ROI 
analysis. 
 
2.5 Data analysis 
 Group differences in age and neuropsychiatric assessments were examined by 
one-way ANOVA and post-hoc test with Bonferroni’s correction, and gender 
composition was tested by Pearson’s Chi-Square test. Comparison of motor symptom 
between the two PD groups was assessed by independent sample t-test. 
Measurement of subcortical and limbic magnetic susceptibility was performed in the 
subject’s native space by applying the ROIs on the QSM images. The measured 
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susceptibility value of each structure was adjusted by normalizing the relative 
magnetic permeability of the structures to that of CSF in the lateral ventricle. The 
normalized structural susceptibility was compared between groups. The ROIs were 
also used to calculate the gross volumes of the subcortical and limbic structures, and 
the measured volumes were normalized to that of the whole brain volume for each 
subject before statistical comparison. All comparisons were performed with the SPSS 
Statistics Package v.22 (IBM Corporation, New York, U.S.) at the significance level of 
p < 0.05. One-way ANCOVA and post-hoc test with Bonferroni’s correction were 
employed for multiple group comparison. Age and gender were considered as 
confounding factors and were adjusted in the analysis. For each significant result 
observed, the assumption of linear relationship between covariates and the 
measured susceptibility was evaluated. Group interaction effect between the 
covariates and the normalized structural susceptibility was incorporated into the 
ANCOVA model to examine the effect of covariates on the measured susceptibility. To 
account for the statistical analyses of multiple ROIs in this study, Benjamini-Hochberg 
procedure (BH) was employed to control the false discovery rate (FDR) at the level of 
0.05. 
 
Correlation between equivalent levodopa dosage and subcortical or limbic 
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structure volume of the two PD groups was examined by Pearson’s correlation test to 
assess the effect of medication on brain atrophy. Correlation between structural 
magnetic susceptibility and psychiatric status of the subjects, represented by the 
neuropsychiatric scores, was examined with non-parametric Spearman’s rank 
correlation test. Effects of age and gender were adjusted in the analyses. 
 
3 Results 
3.1 Demographics and neuropsychiatric assessment 
Demographics and results of the neuropsychiatric assessments are tabulated in 
Table 1. Significant difference existed between the mean ages of the three groups. 
Post-hoc test showed that mean age of PDD patients was significantly higher than 
the other two groups (p < 0.01). No significant difference was observed in gender 
composition (p = 0.29). Differences in motor symptom scores and duration of illness 
between the two PD groups were examined. While the two PD groups showed 
similar duration of illness (p = 0.08) and similar PD stage by Hoehn & Yahr staging (p = 
0.90), the UPDRS-III of PDD patients was found to be significantly higher than that of 
the non-demented PD patients (p < 0.001). No significant differences were observed 
in the L-Dopa equivalent dosage for the two PD groups (p = 0.125). 
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Neuropsychiatric assessment results were compared with one-way ANOVA, and 
significant differences between the three groups were observed in all tests. Post-hoc 
test suggested that PDD patients had significantly worse scores than the other two 
groups in the PPRS, PANSS and MMSE assessments (p < 0.001, all), and worse than 
the healthy controls for MADRS-S (p = 0.006) and Y-BOCS (p = 0.012). 
 
3.2 Iron loading by measuring magnetic susceptibility 
 Average magnetic susceptibility measured for each subcortical and limbic 
structure was compared between the three groups, and the results are summarized 
in Figures 2 and 3, with Figure 2 indicating the result of one-way ANCOVA while 
Figure 3 showing the results of the post-hoc test. One-way ANCOVA at the FDR level 
of 0.05, adjusted for age and gender, showed significant group differences for left 
and right hippocampus (p = 0.015 & 0.032, respectively, BH corrected) and right 
thalamus (p = 0.032, BH corrected). Post-hoc test with multiple comparison 
correction suggested higher magnetic susceptibility in PDD patients than healthy 
controls in the left and right hippocampus (p = 0.001 & 0.047, respectively, 
Bonferroni’s corrected). PDD patients also had higher susceptibility than the 
non-demented PD patients in left hippocampus (p = 0.046, Bonferroni’s corrected). 
Significance observed for the right thalamus was due to the significant difference 
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between non-demented PD patients and healthy controls (p = 0.005, Bonferroni’s 
corrected) after post-hoc test. The PD patients were also found to had higher 
magnetic susceptibility than the healthy controls in the right hippocampus (p = 0.006, 
Bonferroni’s corrected).  
 
 The linear relationship between age and measured susceptibility of bilateral 
hippocampus and right thalamus was evaluated with linear regression. Susceptibility 
of bilateral hippocampus showed a moderate correlation with age (left hippocampus: 
r = 0.384, p = 0.001; right hippocampus: r = 0.396, p = 0.001). For right thalamus, 
insignificant linear correlation was observed (r = 0.026, p = 0.836). Group interaction 
effects between age and the measured susceptibility of the three brain structures 
were examined and result of all three regions were found to be insignificant (left 
hippocampus: p = 0.476; right hippocampus: p = 0.494; right thalamus: p = 0.354). 
 
3.3 Comparison of the volume of subcortical and limbic structures 
 The average normalized volumes of the subcortical and limbic structures were 
generally smaller in the PDD patients, yet no statistical significance was observed for 
all subcortical and limbic structures after FDR adjustment with Benjamini-Hochberg 
procedure. Correlation analysis showed mild positive correlation between levodopa 
dosage and normalized volume of left substantia nigra in the two PD groups, with 
Pearson’s coefficient of 0.333 (p = 0.041). Similar result also observed in left and right 
dentate nucleus, with Pearson’s coefficient of 0.345 (p = 0.034) and 0.336 (p = 0.039), 
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respectively. 
 
3.4 Enlargement of lateral ventricle 
 The size of the lateral ventricle was estimated and compared between the three 
groups and the general trend showed that the size increased with disease 
progression (Figure 4). One-way ANCOVA showed significant group differences (p = 
0.031). Post-hoc test suggested that size of lateral ventricle was significantly larger in 
PDD patients than healthy controls (p = 0.027) while no difference was found 
between the non-demented PD patients and healthy controls. 
 
3.5 Neuropsychiatric correlation 
 There were significant correlations between some of the neuropsychiatric 
scores and bilateral thalamus and hippocampus (Figure 5). Bilateral thalamus showed 
mild positive correlation with PPRS (Correlation coefficient for left thalamus: 0.251, p 
= 0.039; for right thalamus: 0.247, p = 0.043), while bilateral hippocampus displayed 
moderate positive correlation with PPRS (Correlation coefficient for left hippocampus: 
0.259, p = 0.033; for right hippocampus: 0.306, p = 0.011) and PANSS (Correlation 
coefficient for left hippocampus: 0.279, p = 0.021; for right hippocampus: 0.406, p = 
0.001), and moderate negative correlation with MMSE (Correlation coefficient for left 
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hippocampus: -0.329, p = 0.006; for right hippocampus: -0.386, p = 0.001). 
 
4. Discussion 
 Post-mortem and imaging studies pointed to abnormal iron deposition in 
the substantia nigra pars compacta of PD patients (Bartzokis et al., 1999; Graham et 
al., 2000; Griffiths et al., 1999; Hare et al., 2013; Jenner, 1991; Jin et al., 2012; Kosta 
et al., 2006; Rouault and Cooperman, 2006; Sofic et al., 1988), but the role of iron 
accumulation in PD and its involvement in the later overt development of 
neuropsychiatric symptoms in PDD remain elusive. In current study, we found that: 
firstly, increased iron concentration was observed in bilateral hippocampus of PDD 
patients, and right hippocampus and right thalamus of PD patients, as compared to 
healthy controls; secondly, the iron content of bilateral hippocampus was found to be 
moderately correlated with both cognitive function and psychotic symptoms of PD 
patients.   
 
  Our current finding of hippocampal iron accumulation and its correlation 
with psychotic features in PDD patients should be interpreted in the light of current 
research.  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
As a cross-sectional imaging study, causation cannot be inferred and it remains 
unclear if the increased iron level in the hippocampus of the PDD patients is involved 
in the pathogenesis or purely reflects an epiphenomenon of advancing 
neurodegeneration of PD patients and this warrants further investigation of the 
causality by a longitudinal study. Although a few previous studies also reported 
association of hippocampal iron with memory test performance in ageing (Rodrigue 
et al., 2013) and Alzheimer’s disease (Ding et al., 2009), no causality between 
hippocampal iron accumulation and the development of dementia symptom in the 
PDD patients could be inferred. 
 
Our finding of hippocampal involvement in PDD concurred with a few prior 
studies, but nevertheless, the role of hippocampus remains controversial. Several 
studies have reported the association between the limbic structures and the onset of 
cognitive decline or dementia in PD patients (Aarsland et al., 2008; Kalaitzakis et al., 
2009). Previous studies of the similar cohort (by our team) using diffusion tensor 
imaging (DTI) and BOLD fMRI reported that the psychotic symptoms of visual 
hallucination in PD patients is related to the disruption of default mode network 
(DMN), particularly the functional connection between hippocampus with DMN and 
frontal region (Yao et al., 2014a; Yao et al., 2014b), suggesting that pathological 
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changes to hippocampus is associated with the development of psychotic disorder in 
PD. 
 
However, besides mesolimbic and mesocortical dopaminergic pathways being 
involved in cognitive functioning, a number of non-dopaminergic transmitter systems 
are affected in PD (Aarsland et al., 2017). A Positron Emission Tomography study 
(Klein et al. 2010) using multiple radioactive ligands found that dementia and 
psychosis (visual hallucination) in both Dementia with Lewy Bodies (DLB) and PDD 
were related to cholinergic defects and parieto-occipital hypometabolism 
respectively. Another Single Photon Emission Computed Tomography study (Mori et 
al., 2006) using 99mTc-HMPAO similarly found that visual hallucinations in DLB could 
be normalized with cholinesterase inhibitors due to increased perfusion in posterior 
visual association cortex.  
 
The thalamus is known to function as a hub for information transfer between 
cerebral cortex and basal ganglia, the structure is highly involved in regulation of 
different motor and non-motor functions. In the current study, higher iron content is 
observed in the unilateral thalamus in the non-demented PD patients, which a 
similar result has been reported in a previous study (Langkammer et al., 2016). Other 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
studies also suggested possible structural abnormalities in thalamus of PD patients 
(Danti et al., 2015; Deng et al., 2016; Gerrits et al., 2016). This study suggests the 
plausible involvement of thalamus in development of PD’s motor symptoms with the 
deposition of iron in the structures. While the PDD group does not show significance 
after post-hoc test in this study, this could be possibly explained by the small sample 
size of the group.  
 
We observed significant enlargement of the lateral ventricle of PDD patients vs 
healthy controls, which has been commonly observed and reported in AD-type 
dementia (Förstl et al., 1995; Luxenberg et al., 1987), and PD patients with mild 
cognitive impairment (MCI) (Dalaker et al., 2011). These suggest that cognitive 
impairment in neurodegenerative disease is closely related to the underlying brain 
atrophy as reflected by enlargement of lateral ventricle. 
 
The effect of medication, i.e. prescription of levodopa for treatment of PD, and 
its relationship with the result of this study is uncertain. We assessed the correlation 
of levodopa dose with normalized volume of different brain region and controlled for 
age and gender of the patients. It was observed that left substantia nigra and 
bilateral dentate nucleus showed positive correlation with levodopa dosage, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
suggesting possible effect of levodopa in preserving the deep brain grey matter 
nuclei in the PD patients.  
 
The effect of age on the brain iron accumulation of healthy subjects, as well as 
PD patients, has been previously demonstrated (Acosta-Cabronero et al., 2016; 
Acosta-Cabronero et al., 2017). While no significant association between age and 
hippocampal iron content was observed in healthy subjects (Acosta-Cabronero et al., 
2016), moderate age-dependent effect of hippocampal iron was reported in PD 
patients (Acosta-Cabronero et al., 2017). To account for the effect of age, one-way 
ANCOVA with age as a covariate was performed. The effect of age on the measured 
magnetic susceptibility of hippocampus was further examined by linear regression of 
age and measured susceptibility and incorporating the group interaction of the two 
terms into the ANCOVA model. The moderate correlation between age and 
measured susceptibility of hippocampus supported the use of ANCOVA to adjust the 
effect of age. It was also demonstrated that interaction effect was not significant in 
the statistical model adopted in this study, and age had the same effect on the 
measured susceptibilities in all three groups. This result supported the claim that the 
differences of hippocampal iron observed in this study shall be mainly due to the 
differences between groups. 
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One of the major limitations of our current study is the sample size of the PDD 
group. In this study, the PDD group consisted of 10 patients only, as opposed to 27 
healthy controls and 31 non-demented PD patients. However, it should be noted that 
the PDD group is difficult to recruit due to the very stringent inclusion and exclusion 
criteria of the group. Since the current study is cross-sectional in design, the 
correlation of increased iron level in the hippocampus of the PDD patients and the 
neuropsychiatric scores could be non-specific and due to parallel association, both 
features simply reflecting advanced disease state. A longitudinal study is warranted 
to further investigate the role of iron in the pathogenesis of advancing 
neurodegeneration of PD patients and its plausible causality to the memory decline 
in PDD. In this study, we examined simultaneously quite a number of subcortical and 
limbic structures in each evaluation. To account for the problem of multiple statistical 
tests and concerned with the statistical power in the correction, FDR with 
Benjamini-Hochberg Procedure was adopted to keep the false discovery rate of each 
evaluation to significance level of 0.05. Another limitation of this study is concerned 
with the neuropsychiatric presentation of PD patients. Previous study suggests that 
demented PD patients usually exhibit other non-motor comorbidities, while over 
50% of these patients might have visual hallucination or other psychotic symptoms 
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(Burn and Yarnall, 2014). It would have been ideal to have recruited patients with 
PDD without psychosis; however, the high comorbidity of psychosis in late PD 
suggests that the former is part and parcel of disease progression. It is understood 
that psychotic features in PDD might be related to visuospatial impairment and the 
visual cortex shall be one of the region of interest for the investigation of non-motor 
symptoms in PDD. In this study, however, we did not measure posterior and occipital 
cortical iron load of the patients due to the uncertainty in measuring magnetic 
susceptibility at the cerebral cortex. Finally, one should also note that MMSE is only a 
screening test of cognitive dysfunction, it is not ideal for assessment of memory 
decline in the clinical sense.  
 
5. Conclusion 
In our current study by QSM, higher iron deposition is observed in the bilateral 
hippocampus of the PDD patients as compared to healthy controls. Higher iron 
deposition is also observed in the unilateral hippocampus of the PDD patients when 
compared to non-demented PD patients. Moderate correlation of iron content in the 
PD and PDD patients with both cognitive and other neuropsychiatric impairment is 
found. Our results might provide insight on the relation between the effect of iron 
deposition in Parkinson’s disease and cognitive dysfunction. Future longitudinal study 
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for evaluation of the role of limbic iron concentration by QSM in PD pathogenesis, its 
relationship to dementia and psychosis, and potential as a clinical biomarker in 
monitoring treatment by iron chelation therapy in clinical trials is awaited. 
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Table 1 Demographics and results of neuropsychiatric assessment of healthy controls, 
non-demented PD and PDD patients. 
 Healthy PD PDD p-value 
N 27 31 10 - 
Age (years) 62.0 ± 7.0 63.1 ± 8.3 72.6 ± 5.8 0.001* 
Gender (M:F) 14:13 17:14 8:2 0.29 
Duration of illness (years) n/a 7.6 ± 4.6 12.8 ± 8.1 0.08 
Hoehn & Yahr Stage n/a 2.7 ± 0.8 2.7 ± 1.2 0.90 
UPDRS-III n/a 17.4 ± 9.8 33.7 ± 15.7 < 0.001** 
MMSE 28.8 ± 1.0 28.3 ± 1.7 19.3 ± 5.0 < 0.001** 
PPRS 6.1 ± 0.3 6.6 ± 0.9 9.8 ± 2.9 < 0.001** 
PANSS 30.9 ± 3.3 38.2 ± 8.3 52.9 ± 15.6 < 0.001** 
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MADRS-S 0.4 ± 1.1 2.4 ± 2.8 3.9 ± 3.0 < 0.001** 
Y-BOCS 0.0 ± 0.2 0.9 ± 2.4 3.2 ± 6.3 0.016* 
L-Dopa Equivalence (mg) n/a 663.2 ± 416.8 1174.4 ± 935.6 0.125 
Note: Values on the table are displayed as mean ± S.D. UPDRS-III: Section III (motor examination) of 
the Unified Parkinson’s Disease Rating Scale. MMSE: Mini-Mental State Examination; PPRS: 
Parkinson’s Psychosis Rating Scale; PANSS: Positive and Negative Syndrome Scale; MADRS-S: 
Self-assessment of the Montgomery-Åsberg Depression Rating Scale; Y-BOCS: Yale-Brown Obsessive 
Compulsive Scale. 
 
 
 
Fig. 1 (Upper row) Affine registered 3D-T1-TFE image of one of the PDD patients overlaid with 
the segmented subcortical and limbic structures. The segmentation is performed with 
FIRST. (Lower row) The corresponding L1-regularized QSM images in the three orthogonal 
planes. 
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Fig. 2 Result of one-way ANCOVA comparing the magnetic susceptibility of different subcortical 
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and limbic structures between healthy, PD and PDD groups, with FDR adjusted at level of 
0.05. 
 
Fig. 3 Post-hoc test with Bonferroni’s correction accounts for multiple comparison between the 
three groups. Only structures with statistical significance after one-way ANCOVA adjusted 
for FDR are considered for the post-hoc test. Data for left thalamus is included as a 
reference to that of right thalamus. 
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Fig. 4 Comparison of the estimated volume of lateral ventricle between healthy, non-demented 
PD and PDD groups. 
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Fig.5 Scatter plots showing the relationship between the measured susceptibility of bilateral 
hippocampus and (a) PANSS score, (b) MMSE score, (c) PPRS score; (d) bilateral thalamus 
and PPRS score. 
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Highlights 
 This study explore association between brain iron and cognitive impairment in 
PD. 
 QSM shows iron accumulation in the hippocampus of PDD patients. 
 Iron in the hippocampus is correlated with cognitive function of PD patients. 
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